BOOST Pharma Appoints Leading Biopharma Leader Elaine Jones as Chair
- Seasoned life science investor, executive and board leader to support next phase of growth as BOOST Pharma advances BT-101, a promising and potentially disease-modifying therapy for osteogenesis imperfecta
Stockholm, Sweden, March 19, 2026 – BOOST Pharma (“BOOST” or the “Company), a clinical‑stage biopharmaceutical company developing novel, first‑in‑class off-the-shelf cell therapies for rare, debilitating pediatric skeletal diseases, today announced the appointment of highly respected industry leader Elaine Jones, PhD, as Chair of its Board of Directors. Elaine succeeds Ingelise Saunders, who will remain on the Board.
